// App-Quantinova.ai

OC 40.1 : FRONTIER1: A Phase 1/2 Dose Escalation Study of a Novel Factor VIIIa Mimetic Bispecific Antibody, Mim8, for Evaluation of Safety, Pharmacokinetics, and Efficacy

Researchers

Presenter

  • P. Chowdary

Principal Investigators

  • J. Mahlangu

  • P. Persson

  • J. Windyga

Medical Centers

  • The Royal Marsden Hospital, London, United Kingdom

  • Hospital Universitario Regional de Málaga, Malaga, Spain

  • University of Witwatersrand, Johannesburg, South Africa

  • Novo Nordisk A/S, Måløv, Hovedstaden, Denmark

  • Institute of Hematology and Transfusion Medicine, Warsaw, Poland

Locations

  • United Kingdom

  • Spain

  • South Africa

  • Denmark

  • Poland

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Placebo Control

  • Pharmacokinetics

  • Single Ascending Dose

  • Multiple Ascending Dose

  • Dose Escalation

  • Cohort

Phase

  • I/II

Study Id's

  • NCT04204408

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved